Strides Arcolab receives US FDA nod for HIV drug

NEW DELHI: Drug firm Strides Arcolab today said it has received tentative approval from US health regulator for fixed dose combination of Lamivudine and Zidovudine tablets, used in the treatment of human immunodeficiency virus (HIV) in the American market.

The company has received nod for its abbreviated new drug application (ANDA) from US Food and Drug Administration for the fixed dose combination of Lamivudine and Zidovudine tablets in strengths of 150 and 300 mg, Strides Arcolab said in a statement.

The company has got the approval under expedited review provisions of the President's Emergency Plan for AIDS Relief (PEPFAR), it added.

Shares of Strides Arcolab were today trading at Rs 420 on the Bombay Stock Exchange in late afternoon trade, down 2.69 per cent from its previous close.